

Figure S1. Kaplan–Meier analysis of event-free survival (EFS) and overall survival (OS) by RECIST objective response of the primary tumor (**A,B**) and pretreatment TGR₀ (**C,D**) in a subgroup of patients treated by neoadjuvant nivolumab-based therapy. p -values were obtained using the log-rank test.





Figure S2. Kaplan–Meier analysis of event-free survival (A) and overall survival (B) by major pathological response (MPR). p -values were obtained using the log-rank test. EFS: event-free survival; OS: overall survival..